Skip to main content
Premium Trial:

Request an Annual Quote

And All Under 140 Characters

The long-awaited US Food and Drug Administration guidance on social media for drug companies has arrived, and it includes information on how to discuss the risks and benefits of drugs on a social media platform like Twitter and how to correct misinformation present on websites like Wikipedia, Pharmalot's Ed Silverman writes.

A tweet promoting the benefit of a drug — the brand and generic name of which must be included — needs to also incorporate the top risk associated with it as well as a link to a site that describes all possible harms, Bloomberg reports. FDA offered this as an example of such a tweet: "NoFocus (rememberine HCl) for mild to moderate memory loss-May cause seizures in patients with a seizure disorder" This tweet, which refers to a fictional drug, Bloomberg notes, uses 134 of the 140 characters allowed by Twitter.

"I think this is clear enough guidance you'll start seeing more tweets," Lori Leskin, a partner at the New York law firm Kaye Scholer, tells Bloomberg. "It's the more significant drugs that do have black box warnings, that do have more significant risk, that are used in limited populations that this won't be appropriate for."

The guidance also suggests that drug companies may also correct misinformation on third-party sites, provided they provide balance information and credits the company, company employee, or contractor with the fix, Silverman says.

"The information should not be promotional and should be factually correct. This is not an opportunity for a company to tout its drugs," Tom Abrams, from the Office of Prescription Drug Promotion at FDA, tells Pharmalot. "The information [being added or revised] should be consistent with the FDA-approved [product] labeling and for it to be effective, you want it posted right by the misinformation."

The Scan

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.

New Oral Nanomedicine Strategy Targets Gut-Brain Axis to Treat IBD

A new paper in Science Advances describes a platform to design polyphenol-armored oral medicines that are effective at treating inflammatory bowel disease.

Phylogenetic Data Enables New Floristic Map

Researchers in Nature Communications use angiosperm phylogenetic data to refine the floristic regions of the world.

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.